KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Rigel Pharmaceuticals (RIGL) over the last 17 years, with Q3 2025 value amounting to $24.0 million.

  • Rigel Pharmaceuticals' Free Cash Flow rose 1084.92% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.2 million, marking a year-over-year increase of 53527.22%. This contributed to the annual value of $31.4 million for FY2024, which is 64736.2% up from last year.
  • According to the latest figures from Q3 2025, Rigel Pharmaceuticals' Free Cash Flow is $24.0 million, which was up 1084.92% from $30.5 million recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Free Cash Flow ranged from a high of $54.8 million in Q2 2021 and a low of -$25.9 million during Q1 2022
  • Over the past 5 years, Rigel Pharmaceuticals' median Free Cash Flow value was -$4.1 million (recorded in 2023), while the average stood at $548421.1.
  • Its Free Cash Flow has fluctuated over the past 5 years, first tumbled by 44124.32% in 2021, then skyrocketed by 1001158.94% in 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Free Cash Flow (Quarter) stood at -$19.1 million in 2021, then dropped by 15.3% to -$22.0 million in 2022, then surged by 71.61% to -$6.2 million in 2023, then soared by 332.0% to $14.5 million in 2024, then surged by 65.99% to $24.0 million in 2025.
  • Its Free Cash Flow was $24.0 million in Q3 2025, compared to $30.5 million in Q2 2025 and -$893000.0 in Q1 2025.